Bioequivalence and Bioavailability Forum 14:42 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Obinoscopy
Regular

Nigeria,
2018-10-01 14:38

Posting: # 19351
Views: 219
 

 FDA Recommendation on Matrix Effect Determination in CC Assay [Bioanalytics]

Hi Guys,

I am going through the FDA BMV guideline and I noticed they didn't give any specific guidance on how to validate that a Chromatographic Assay method is free from Matrix Effect.

All I saw was this:

"Sponsor should ensure that there are no matrix effect throughout the application of the method"

No detail on how this could be achieved was provided.

For Ligand Binding Assays, they did give some hint on how to evaluate Matrix Effect but no Acceptance Criteria was provided.

Why is this so? Could it be that there are different school of thoughts on how to evaluate matrix effect and the FDA is trying not to take sides?

I personally feel they should have provided a method of evaluating matrix effect. Either they provide that which is in tandem with the EMA or they provide an alternative.

Or what do you think?

Regards,

Scopy
Ohlbe
Hero

France,
2018-10-01 15:30

@ Obinoscopy
Posting: # 19353
Views: 205
 

 FDA Recommendation on Matrix Effect Determination in CC Assay

Dear Scopy,

» I am going through the FDA BMV guideline and I noticed they didn't give any specific guidance on how to validate that a Chromatographic Assay method is free from Matrix Effect.

True. I find this is a real gap in their new Guidance. There was nothing about it in the 2001 Guidance, and not much more here, though matrix effects are a real pain in the quadrupole and can be dangerous.

» Why is this so? Could it be that there are different school of thoughts on how to evaluate matrix effect and the FDA is trying not to take sides?

No idea. I know that the FDA is trying not to be overly prescriptive, but they are giving much more details on other aspects of method validation.

We'll see what makes it into the ICH draft.

Regards
Ohlbe
ElMaestro
Hero

Denmark,
2018-10-01 16:30

@ Ohlbe
Posting: # 19355
Views: 196
 

 FDA Recommendation on Matrix Effect Determination in CC Assay

Hello both,

is there any method published anywhere which can be realistically thought to have no matrix effect?
Not just absence of mentioned effect, but truly verified absence of one and how would one go about proving it?

If you had a gun pointed to your head and someone asks you to develop an LC-MS/MS method without matrix effect for, say, Duloxetine or Simvastatin where would you start?

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
Ohlbe
Hero

France,
2018-10-01 17:20

@ ElMaestro
Posting: # 19356
Views: 194
 

 Reducing matrix effects

Dear ElMaestro,

» is there any method published anywhere which can be realistically thought to have no matrix effect?
» Not just absence of mentioned effect, but truly verified absence of one and how would one go about proving it?

Define "no matrix effect". Same as concentration = 0: truly 0, or BLQ ? No matrix effect, or negligible ? Considering the analytical variability, I would consider it strictly impossible to demonstrate 0.000 matrix effect.

» If you had a gun pointed to your head and someone asks you to develop an LC-MS/MS method without matrix effect for, say, Duloxetine or Simvastatin where would you start?

Our Father who art in heaven...

I would start with:

  1. using matrix obtained the same way as subject samples (vacutainers, not commercial plasma collected in blood collection bags full of plasticisers)
  2. a real, proper sample cleaning (SPE or LLE, with a real development to really clean up, without too much loss in recovery. For instance, MTBE usually gives you a very good recovery of your drug... but also of quite a lot of things you'd like to get rid of)
  3. a real chromatography (not a 90 seconds run on a 30 mm column)
  4. comparing APCI and ESI. APCI is supposed to be less sensitive to matrix effects. Unfortunately, it is also less sensitive, full stop. May be problematic if a very low LLOQ is required (would not work for a number of the molecules you're working on).

And that's if I limit the definition of matrix effects to differences in detector response. You could expand the definition to include differences in recovery.

Regards
Ohlbe
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,761 posts in 3,996 threads, 1,258 registered users;
online 16 (0 registered, 16 guests [including 10 identified bots]).

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed